Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N05AX13

Byannli (previously Paliperidone Janssen-Cilag International)(paliperidone palmitate)

Schizophrenia

Marketing Authorisation Holder: Janssen-Cilag International N.V.

EMA Authorisation: 18/06/2020

INN: paliperidone

Indication

Byannli (previously Paliperidone Janssen-Cilag International) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.1).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Byannli (previously Paliperidone Janssen-Cilag International) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.